Laparoscopy firm SurgRx attracts former Novacept backer in fundraising
This article was originally published in Clinica
New Enterprise Associates, the long-established venture capital firm that backed Novacept through to its acquisition by Cytyc for $325m last year, has led a $21m investment round in SurgRx. Menlo Park, California-based SurgRx has developed an FDA-approved laparoscopic instrument, EnSeal, that operates via a radiofrequency controller and "Smart Electrode" sensor to cut and seal blood vessels and tissue while minimising thermal damage to adjacent tissue.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.